EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis

Jiefeng Luo iD, Zhengxiong Li, Jun Ge, Sizhen Cai, Xinyi Mo, Wensheng Liu, Chengxia Gui, Qiong Du, Jiyong Liu

Cancer · 01.02.2026 · 132 (3)

DOI: 10.1002/cncr.70259 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer, online erschienen am 01.02.2026. Verfasst von Jiefeng Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Sorafenib. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab plus ipilimumab has shown survival benefits as first‐line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost‐effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer perspective.

Methods

A partitioned survival model was developed using data from the CheckMate 9DW trial with a 10‐year horizon. Costs and outcomes were discounted by 3% annually. Clinical inputs were derived from CheckMate 9DW trial, and cost inputs were obtained from public databases and published studies. Primary outcomes were quality‐adjusted life years (QALYs), total costs, life years (LYs), and incremental cost‐effectiveness ratios (ICERs). Sensitivity and scenario analyses were conducted to test uncertainties.

Results

Nivolumab plus ipilimumab produced an incremental gain of 0.66 QALYs at an additional cost of $132,652, yielding an ICER of $200,409/QALY, above US willingness‐to‐pay thresholds ($100,000/QALY and $150,000/QALY). Probabilistic sensitivity analysis indicated a low probability of cost‐effectiveness at current prices (4.6%–20%). Scenario analyses showed that extending maintenance nivolumab dosing from every 4 weeks to every 8 weeks reduced the ICER to $82,202/QALY, making the regimen cost‐effective. Moderate price reductions also substantially increased the likelihood of cost‐effectiveness.

Conclusions

Nivolumab plus ipilimumab is unlikely to be cost‐effective as first‐line therapy for unresectable HCC from US health care payer perspective. However, extended dosing interval or price reductions may render the regimen economically viable, with important implications for clinical practice, payers, and policy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsSorafenibNivolumabIpilimumabAntineoplastic Combined Chemotherapy ProtocolsQuinolinesHumansCost-Benefit AnalysisCost-Effectiveness AnalysisQuality-Adjusted Life YearsUnited States

Stichwörter der Autor:innen

cost‐effectiveness analysishepatocellular carcinomaipilimumablenvatinibnivolumabsorafenib

Substanzen

Phenylurea CompoundsSorafenibNivolumabIpilimumablenvatinibQuinolines

Autor:innen und Institutionen

  • Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • School of Medical Informatics and Engineering, Xuzhou Medical University, Xuzhou, China.
  • School of Chemistry, Sun Yat-sen University, Guangzhou, China.
  • School of Pharmacy, Guangzhou Medical University, Guangzhou, China.
  • Department of Internal Medicine, Sichuan Electric Power Hospital, Chengdu, China.

ORCID-Profile: Jiefeng Luo

Zitieren

APA

Luo, J., Li, Z., Ge, J., Cai, S., Mo, X., Liu, W., Gui, C., Du, Q., & Liu, J. (2026). Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer, 132(3). https://doi.org/10.1002/cncr.70259

Vancouver

Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer. 2026;132(3). doi:10.1002/cncr.70259

BibTeX
@article{Luo2026,
  author = {Luo, Jiefeng and Li, Zhengxiong and Ge, Jun and Cai, Sizhen and Mo, Xinyi and Liu, Wensheng and Gui, Chengxia and Du, Qiong and Liu, Jiyong},
  title = {Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {3},
  doi = {10.1002/cncr.70259}
}
Kostenlos starten →